Cargando…

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial

BACKGROUND: Liraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it could enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensterle, Mojca, Kravos, Nika Aleksandra, Goričar, Katja, Janez, Andrej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286837/ https://www.ncbi.nlm.nih.gov/pubmed/28143456 http://dx.doi.org/10.1186/s12902-017-0155-9

Ejemplares similares

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
por: Kravos, Nika Aleksandra, et al.
Publicado: (2021)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
por: Jensterle, Mojca, et al.
Publicado: (2019)

SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

Effects of liraglutide on obesity-associated functional hypogonadism in men
por: Jensterle, M, et al.
Publicado: (2019)

SLC6A4 5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome
por: Šenk, Barbara, et al.
Publicado: (2018)

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport
por: Herman, Rok, et al.
Publicado: (2022)

Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome
por: Herman, Rok, et al.
Publicado: (2020)

The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age
por: Podbregar, Ana, et al.
Publicado: (2020)

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
por: Frøssing, Signe, et al.
Publicado: (2017)

Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly
por: Herman, Rok, et al.
Publicado: (2022)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density
por: Chen, Kai, et al.
Publicado: (2021)

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
por: Ferjan, Simona, et al.
Publicado: (2019)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
por: Liu, Ying, et al.
Publicado: (2017)

MON-220 Androstendione Affects Endometrial Gene Expression Profile During Window of Implantation in Obese Infertile Women with PCOS
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
por: Chua, Marvin Wei Jie
Publicado: (2021)

Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
por: Xing, Chuan, et al.
Publicado: (2022)

Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance
por: Simanenkova, Anna, et al.
Publicado: (2021)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Efficacy and safety of liraglutide in Indian adolescents with obesity
por: Kochar, I. S., et al.
Publicado: (2019)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili, Heshma, et al.
Publicado: (2021)

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity
por: Carlsson Petri, Kristin C., et al.
Publicado: (2021)

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
por: Lu, Ran, et al.
Publicado: (2018)

Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide
por: Ishihara, Yo, et al.
Publicado: (2022)

High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery
por: Vinciguerra, Federica, et al.
Publicado: (2023)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study
por: Podbregar, Ana, et al.
Publicado: (2021)

Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients
por: Martines, Gennaro, et al.
Publicado: (2023)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

Liraglutide and obesity: a review of the data so far
por: Ladenheim, Ellen E
Publicado: (2015)

Liraglutide restores impaired associative learning in individuals with obesity
por: Hanssen, Ruth, et al.
Publicado: (2023)

Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects
por: Wang, Zhang, et al.
Publicado: (2017)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
por: Zhao, Xu, et al.
Publicado: (2019)

Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
por: Sanyal, Debmalya, et al.
Publicado: (2013)

Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
por: Janez, Andrej, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s4vo0gddvthb96nbtt2h7jejue